# Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations

> **NCT06655064** · — · TERMINATED · sponsor: **Telix Pharmaceuticals (Innovations) Pty Limited** · enrollment: 120 (actual)

## Conditions studied

- Prostate Cancer (Adenocarcinoma)

## Interventions

- **OTHER:** None- Observational

## Key facts

- **NCT ID:** NCT06655064
- **Lead sponsor:** Telix Pharmaceuticals (Innovations) Pty Limited
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2025-01-30
- **Primary completion:** 2025-06-17
- **Final completion:** 2025-06-17
- **Target enrollment:** 120 (ACTUAL)
- **Why stopped:** Sponsor request
- **Last updated:** 2025-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06655064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06655064, "Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06655064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*